Samsung Biologics (Korea) Today
| 207940 Stock | 953,000 24,000 2.58% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Samsung Biologics is trading at 953000.00 as of the 28th of November 2024, a 2.58 percent increase since the beginning of the trading day. The stock's open price was 929000.0. Samsung Biologics has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Samsung Biologics Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Moving together with Samsung Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Samsung Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Samsung Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Samsung Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Pres CEO | John Rim |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Samsung Biologics Co (207940) is traded on Korea Stock Exchange in Korea and employs 10 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 57.3 T. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Samsung Biologics's market, we take the total number of its shares issued and multiply it by Samsung Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Samsung Biologics operates under Healthcare sector and is part of Biotechnology industry. The entity has 71.17 M outstanding shares.
Samsung Biologics generates positive cash flow from operations, but has no cash available
Check Samsung Biologics Probability Of Bankruptcy
Ownership AllocationSamsung Biologics shows a total of 71.17 Million outstanding shares. Samsung Biologics has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 75.18 % of Samsung Biologics outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Samsung Ownership Details
Samsung Biologics Risk Profiles
Although Samsung Biologics' alpha and beta are two of the key measurements used to evaluate Samsung Biologics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.8992 | |||
| Semi Deviation | 1.21 | |||
| Standard Deviation | 1.47 | |||
| Variance | 2.16 |
Samsung Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Samsung Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Samsung Biologics Corporate Management
Elected by the shareholders, the Samsung Biologics' board of directors comprises two types of representatives: Samsung Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Samsung. The board's role is to monitor Samsung Biologics' management team and ensure that shareholders' interests are well served. Samsung Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Samsung Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hoyeol Yoon | Ex VP | Profile | |
| James Park | MD VP | Profile | |
| Doyoung Heo | VP Relations | Profile | |
| James Choi | Chief VP | Profile | |
| Hyung Moon | Head VP | Profile | |
| Andy Kim | Exec center | Profile |
Other Information on Investing in Samsung Stock
Samsung Biologics financial ratios help investors to determine whether Samsung Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Samsung with respect to the benefits of owning Samsung Biologics security.